Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ditmarsch

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Pharmacology Research & Perspectives|October 19, 2024
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trialsStephen J Nicholls, Adam J Nelson, John J P Kastelein, et al.
Journal of the American College of Cardiology|September 1, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
Journal of Clinical Lipidology|June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trialChristie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
American Journal of Preventive Cardiology|June 15, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trialsLiffert Vogt, Michael H Davidson, Michael Szarek, et al.
Journal of Atherosclerosis and Thrombosis|April 3, 2024
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 TrialMariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, et al.
Cardiovascular Diabetology|May 15, 2026
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization studyZekai Chen, Rima D Triatin, Li Luo, et al.
The Journal of Prevention of Alzheimer'S Disease|October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular diseaseMichael H Davidson, Michael Szarek, Philip Scheltens, et al.
American Journal of Preventive Cardiology|July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experienceAdam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
European Heart Journal|March 19, 2014
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trialKausik K Ray, Marc Ditmarsch, David Kallend, et al.
American Heart Journal|July 19, 2025
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristicsCian P McCarthy, Christie M Ballantyne, Ron Blankstein, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Pharmacology Research & Perspectives|October 19, 2024
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trialsStephen J Nicholls, Adam J Nelson, John J P Kastelein, et al.
Journal of the American College of Cardiology|September 1, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisStephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
Journal of Clinical Lipidology|June 5, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trialChristie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, et al.
American Journal of Preventive Cardiology|June 15, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trialsLiffert Vogt, Michael H Davidson, Michael Szarek, et al.
Journal of Atherosclerosis and Thrombosis|April 3, 2024
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 TrialMariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, et al.
Cardiovascular Diabetology|May 15, 2026
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization studyZekai Chen, Rima D Triatin, Li Luo, et al.
The Journal of Prevention of Alzheimer'S Disease|October 18, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular diseaseMichael H Davidson, Michael Szarek, Philip Scheltens, et al.
American Journal of Preventive Cardiology|July 3, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experienceAdam J Nelson, John Jp Kastelein, Marc Ditmarsch, et al.
European Heart Journal|March 19, 2014
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trialKausik K Ray, Marc Ditmarsch, David Kallend, et al.
American Heart Journal|July 19, 2025
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristicsCian P McCarthy, Christie M Ballantyne, Ron Blankstein, et al.
Pageof 4